Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Chen KT, Madison R, Moore J, Jin D, Fleischmann Z, Newberg J, Schrock A, Bhardwaj N, Lofgren KT, He J, Frampton G, Hegde P, Fabrizio D, Pishvaian MJ, Ebot E, Singhi A, Sokol E. Chen KT, et al. Among authors: pishvaian mj. Oncologist. 2023 Aug 3;28(8):691-698. doi: 10.1093/oncolo/oyad178. Oncologist. 2023. PMID: 37354528 Free PMC article.
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.
Singh H, Xiu J, Kapner KS, Yuan C, Narayan RR, Oberley M, Farrell A, Surana R, Huffman BM, Perez K, Cleary JM, Jordan AC, Dias Costa A, Williams HL, Raghavan S, Weinberg B, Pishvaian MJ, Shroff RT, Goel S, Dougan SK, Nowak JA, Spetzler D, Sledge G, Wolpin BM, Aguirre AJ. Singh H, et al. Among authors: pishvaian mj. Clin Cancer Res. 2024 Nov 1;30(21):4932-4942. doi: 10.1158/1078-0432.CCR-24-1164. Clin Cancer Res. 2024. PMID: 39283131
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, Cho DC, Rizvi NA, Sznol M, Lutzky J, Bauman JE, Bitting RL, Starodub A, Jimeno A, Reardon DA, Kaley T, Iwamoto F, Baehring JM, Subramaniam DS, Aragon-Ching JB, Hawthorne TR, Rawls T, Yellin M, Keler T. Sanborn RE, et al. Among authors: pishvaian mj. J Immunother Cancer. 2022 Aug;10(8):e005147. doi: 10.1136/jitc-2022-005147. J Immunother Cancer. 2022. PMID: 35940825 Free PMC article.
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, Awada A, Camidge DR, Hodi FS, McArthur GA, Miller WH, Cervantes A, Chow LQ, Lesokhin AM, Rutten A, Sznol M, Rishipathak D, Chen SC, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu LL. Kim TW, et al. Among authors: pishvaian mj. Clin Cancer Res. 2022 Aug 15;28(16):3452-3463. doi: 10.1158/1078-0432.CCR-21-4020. Clin Cancer Res. 2022. PMID: 35699599 Free PMC article. Clinical Trial.
Envisioning the future of precision oncology trials.
Madhavan S, Beckman RA, McCoy MD, Pishvaian MJ, Brody JR, Macklin P. Madhavan S, et al. Among authors: pishvaian mj. Nat Cancer. 2021 Jan;2(1):9-11. doi: 10.1038/s43018-020-00163-8. Nat Cancer. 2021. PMID: 35121893 No abstract available.
93 results